Techlicious

Review of the Quell 2.0 Wearable Pain Relief Device

When NeuroMetrix first unveiled the Quell a few years ago, its promise was a drug-free alternative using the body’s own mechanisms to combat chronic pain. Version 2.0 carries on with the same goal; ...
Nasdaq

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

About one-quarter of U.S. adults suffer from frequent knee pain, which limits function, decreases mobility, impacts sleep and reduces quality of life. Chronic knee pain is typically treated with oral ...
WBOC

Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study

Quell has initiated the CHILL Phase 1/2 trial to explore QEL-005 in refractory rheumatoid arthritis and systemic sclerosis (see separate announcement today) with early clinical data expected during Q1 ...
Seeking Alpha

electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) ...
Techlicious

Review of the Quell 2.0 Wearable Pain Relief Device

New design and features of Quell 2.0 NeuroMetrix focused largely on two things to differentiate version 2.0: make the device smaller, and more functional with the mobile app for iOS and Android. The ...